Blend: GHK-Cu BPC-157 TB-500 Peptide (GLOW)

This page covers three independent papers:

• BPC 157: Matek et al. (2025), Pharmaceutics. A rat quadriceps muscle-to-bone detachment model.
• Thymosin β4: Philp and Kleinman (2010), Annals of the New York Academy of Sciences. A review of animal tissue-repair studies.
• GHK-Cu: Tucker et al. (2024), Aging Pathobiology and Therapeutics. Intranasal GHK-Cu in 5xFAD transgenic mice.

The studies differ in species, model, route, duration and outcomes. Their findings cannot be added together, and they provide no evidence about the compounds' combined effects.

Male Wistar rats had the quadriceps surgically detached and received BPC 157 by mouth, first by stomach tube and then in drinking water, or plain water. Over 90 days, the authors reported that treated rats showed better walking and motor-function scores than controls, elimination of the contracture seen in controls, thigh muscle diameter closer to normal, and imaging and histology consistent with muscle-to-bone reattachment.

Limitations: One rat model, 6 rats per group per time point and male animals only. Much of the BPC 157 literature comes from the same research group.

This narrative review summarizes animal studies of thymosin β4, a 43-amino-acid actin-binding peptide. Topical Tβ4 was associated with faster corneal and skin wound closure in rats and mice. Systemic Tβ4 was associated with better outcomes in mouse and pig heart models, rat brain injury, mouse autoimmune encephalomyelitis and rat endotoxin shock.

Limitations: Each finding comes from a separate study. Most used full-length Tβ4, which may differ from materials sold as TB-500. One author disclosed consulting for a company developing Tβ4.

Male and female 5xFAD transgenic mice, a model of amyloid pathology, received intranasal GHK-Cu or saline three times weekly for 12 weeks. Compared with saline-treated 5xFAD mice, GHK-Cu-treated mice had Y-maze alternation scores comparable to wild-type mice, fewer amyloid plaques and lower MCP-1 staining in the frontal cortex and hippocampus.

Limitations: 4–7 mice per group, one behavioral test and a 12-week study. The authors noted that the nasal safety of repeated dosing needs further study.

• BPC 157: A 15-amino-acid peptide based on a gastric juice protein sequence. It was studied here by oral delivery in a rat muscle-to-bone injury model.
• Thymosin β4: A 43-amino-acid intracellular actin-binding peptide. It was studied by topical and systemic delivery in eye, skin, heart, brain and sepsis models.
• GHK-Cu: A copper-bound tripeptide (glycyl-L-histidyl-L-lysine). It was studied here by intranasal delivery in a transgenic mouse model of amyloid pathology.

The studies measured different outcomes in different tissues, so they cannot be compared directly.

• No referenced study tested these compounds in combination. Claims of complementary, combined or "synergistic" effects would not be supported by these papers.
• None of the studies establishes effects, safety or dosing for any of these compounds in people.
• Findings from one injury or disease model should not be generalized to other models, species or conditions.

The three papers summarized here each describe a single compound in its own experimental animal model: BPC 157 in rat quadriceps detachment, thymosin β4 across a range of animal repair models, and GHK-Cu in 5xFAD mice. The combination of these compounds has not been studied in the referenced literature. Researchers should evaluate each source on its own.

This summary is provided for research and educational purposes. Statements on this page have not been evaluated by the FDA. Research compounds offered on this site are for laboratory research use only. They are not intended for human or veterinary use, or to diagnose, treat, cure, mitigate or prevent any disease.